Contact Us
Drug Search Results
More Filters [+]

MG-1113

Alternative Names: mg-1113, mg 1113, mg1113
Latest Update: 2022-08-25
Latest Update Note: Clinical Trial Update

Product Description

MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695563/)

Mechanisms of Action: TFPI Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GC Biopharma Corp
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MG-1113

Countries in Clinic: Korea

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Hemophilia A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MG1113_HP_P0101

P1

Recruiting

Hemophilia A

2024-07-31

MG1113_P1

P1

Completed

Hemophilia A

2021-06-30

21%

Recent News Events

Date

Type

Title

06/01/2021

PubMed

 Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.

10/22/2020

PubMed

 MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions